비욘드바이오

BEY4101

Blood cancer treatment

An anticancer agent that selectively acts on Cdc2-like kinase (CLK), which controls RNA alternative splicing

Alternative splicing is a process that allows multiple types of proteins to be produced from a single gene, and it is known that approximately 94% of human genes undergo alternative splicing. Abnormal regulation of alternative splicing is reported to be a factor in the occurrence, progression, and metastasis of cancer through cell proliferation, invasion, angiogenesis, and changes in metabolism.

BEY4101 is an anti-cancer agent that promotes cancer cell death by inducing dephosphorylation of SRSF and regulating alternative splicing of genes associated with cancer cell survival (S6K1) and apoptosis (MCL1 and BCLX). In particular, complete remission (CR) of tumors by BEY4101 was confirmed in a non-clinical blood cancer model, and improved anticancer effects were shown when combination with Venetoclax.

Currently, BEY4101 is aiming to enter phase 1 clinical trials for blood cancer in 2026, and expending its scope to colon cancer and lung cancer.